We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Mesoblast Ltd (MESO) ADR each repr 5 NPV

Sell:$6.03 Buy:$6.05 Change: $0.01 (0.17%)
Market closed |  Prices as at close on 30 November 2021 | Switch to live prices |
Change: $0.01 (0.17%)
Market closed |  Prices as at close on 30 November 2021 | Switch to live prices |
Change: $0.01 (0.17%)
Market closed |  Prices as at close on 30 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Mesoblast Limited is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company is using its mesenchymal lineage cell technology platform to develop and commercialize allogeneic cellular medicines to treat complex inflammatory diseases. Its product candidate includes Remestemcel-L ((RYONCIL) for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), Rexlemestrocel-L (REVASCOR) for the advanced chronic heart failure (CHF) and MPC-06-ID for the treatment of chronic low back pain caused by disc degeneration (CLBP). Its product candidate MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction. Its product candidate also includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy.

Contact details

L 38 55 Collins St
+61 (3) 96396036

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$782.76 million
Shares in issue:
647.92 million
US dollar

Key personnel

  • Silviu Itescu
    Chief Executive Officer, Executive Director
  • William Burns
    Non-Executive Independent Vice Chairman of the Board
  • Andrew Chaponnel
    Interim Chief Financial Officer
  • Dagmar Rosa - Bjorkeson
    Chief Operating Officer
  • Peter Howard
    General Counsel, Corporate Executive
  • Fred Grossman
    Chief Medical Officer
  • Justin Horst
    Head of Manufacturing
  • Michael Schuster
    Pharma Partnering
  • Paul Simmons
    Head of Research and New Product Development
  • Geraldine Storton
    Head of Regulatory Affairs and Quality Management

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.